Suven Pharma stock rises 4% on acquisition by Advent International
Advent plans to merge its portfolio company Cohance Lifesciences with Suven to build an end-to-end CDMO and merchant API.
Advent plans to merge its portfolio company Cohance Lifesciences with Suven to build an end-to-end CDMO and merchant API.